Clinical Trials/JPRN-jRCTs031220192

JPRN-jRCTs031220192

Recruiting

Phase 2

Safety and pharmacokinetic study of a new PET probe [18F]FEDAC in patients with suspected malignant tumors

Tamura Kentaro0 sites30 target enrollmentJuly 7, 2022

ConditionsMalignant tumors(solid tumors)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Malignant tumors(solid tumors)
Sponsor: Tamura Kentaro
Enrollment: 30
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 7, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Eligibility Criteria

Inclusion Criteria

•1\.Subjects who are 18 years of age or older at the time of consent acquisition
•2\.Subjects who have been confirmed to have malignant tumors by histopathological examination performed within the past 90 days from the date of consent acquisition or by diagnostic imaging within the past 28 days from the date of consent acquisition
•3\.Subjects whose Performance Status (ECOG PS) is 0 or 1
•4\.Subjects who provide written informed consen

Exclusion Criteria

•1\.Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co\-investigator to be unsuitable for this study
•2\.Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urine test) after obtaining the informed consent
•3\.Subjects with drug addiction or alcohol addiction
•4\.Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study
•5\.Subjects who are unable or restricted from the tests specified in the research plan
•6\.Subjects who are claustrophobic
•7\.Subjects who is considered to be inappropriate to participate in this study by the investigator or co\-investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

First in Human study of a New PET Probe FEDAC

JPRN-jRCTs031210134Tamura Kentaro10

Active, not recruiting

A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents

EUCTR2008-003917-29-GBGilead Sciences Incorporated24

Active, not recruiting

Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.

EUCTR2018-001516-30-BGGUERBET60

Active, not recruiting

Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance ImagingMedDRA version: 22.1Level: LLTClassification code 10029817Term: Nuclear magnetic resonance imaging brainSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10072232Term: Nuclear magnetic resonance imaging spinalSystem Organ Class: 100000004848Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

EUCTR2018-001516-30-PLGUERBET80

Active, not recruiting

Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.

EUCTR2018-001516-30-SKGUERBET80